Inflammatory bowel disease. Part II: Crohn's disease--pathophysiology and conventional and alternative treatment options (original) (raw)
Related papers
Crohn’s disease: Symptoms, diagnosis, management by medical and alternative treatment
Pharmaceutical Sciences Asia, 2021
Crohn's Disease (CD) insinuates to chronic inflammation of the intestine where the inflammation is greatly T-cell mediated. The perception of CD at present stretch is restricted, public health inspections are carried out as it supports eminent aptitude. It's more common in the developed countries. CD is a recurrent, dynamic and deadly infection. CD is not easy to diagnose due to the overlapping symptoms. It has been elucidated that CD commonly develops at a young age, usually before the age of 17. About 20% of the population suffering from CD is most commonly linked with family background bearing inflammatory bowel diseases (IBD). This review elucidates the history, epidemiology, etiology, signs and symptoms, pathophysiology, diagnosis and treatment of CD for better management and to provide appropriate treatment for the disease. No permanent cure of the disease is yet known but the symptoms of the disease can be managed through medication, surgical resection and some alternative medicines for cure of this disease.
Foods
Crohn’s disease (CD) is a chronic inflammatory gastrointestinal disorder requiring lifelong medications. The currently approved drugs for CD are associated with relevant side effects and several studies suggest an increased use of nutraceuticals among CD patients, seeking for what is perceived as a more “natural” approach in controlling this highly morbid condition. Nutraceuticals are foods or foods’ components with beneficial health properties that could aid in CD treatment for their anti-inflammatory, analgesic and immunoregulatory activities that come along with safety, high tolerability, easy availability and affordability. Depending on their biological effect, nutraceuticals’ support could be employed in different subsets of CD patients, both those with active disease, as adjunctive immunomodulatory therapies, and/or in quiescent disease to provide symptomatic relief in patients with residual functional symptoms. Despite the increasing interest of the general public, both limit...
Crohn’s Disease: A Review on Epidemiology, Diagnosis and Therapeutic Management
Indian Drugs
Crohn’s disease (CD) is a kind of inflammatory bowel disease (IBD) characterized by the chronic transmural inflammatory state of gastrointestinal tract that typically affects ileum, colon, and perineum. Although the precise etiology is unknown, the major risk aspects concerned with CD consist of several environmental factors, altered microbiota, unhealthy low fiber- high carbohydrate diet, and certain medicines like non-steroidal anti-inflammatory drugs. The disease has wide distribution and inflammation may affect the different areas of the alimentary tract in diverse people. In about 80 % of patients, only small bowel involvement is typically present, affecting distal ileum resulting in ileitis. In about 50 % patients, both ileum and colon are affected resulting in ileocolitis and in approximately 20 % patients, disease is limited to colonic portion. Perianal disease affects almost one-third of patients. As per the various genetic researches in the CD patients, various genetic mut...
The role of dietary factors in inflammatory bowel diseases: New perspectives
Journal of Digestive Diseases, 2018
The current review aimed to elucidate the role of diet in every stage of inflammatory bowel disease, from aspects of prevention, treatment and rehabilitation. Western diet, characterized by overconsumption of refined sugar, saturated fat and low consumption of dietary fiber, may partly be blamed for its pathogenesis. Some immune-modulated nutrients (fibers, monounsaturated fatty acids, n-3 polyunsaturated fatty acids and vitamin D) exert their potential beneficial effects on gut microbiota and immune function, resulting in clinical remission and/or preventing relapse. However, data is limited to conclude optimal micronutrient levels and therapeutic implications. Further, diet itself is complex; it is reasonable to evaluate diet as a whole rather than a single type of food. Some specific dietary patterns are generated for the management of inflammatory bowel diseases with controversial results. Only exclusive enteral nutrition has been widely recommended for pediatric patients with non-stricture active Crohn"s disease. Self-monitor, avoidance of certain This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as
Nutritional Therapy in Crohnʼs Disease
Inflammatory Bowel Diseases, 1998
The value of nutritional support in the prevention and treatment of malnutrition in Crohn's disease is undisputed but its role in primary therapy continues to be debated. Controlled trials have demonstrated that enteral nutrition induces remission rates comparable to that of corticosteroid therapy in Crohn's disease and remains the treatment of choice for specific subgroups such as children with signs of' growth impairment and patients with intolerable steroid-induced side effects. The mechanism by which an enteral diet induces remission in Crohn's disease is unclear. Bowel rest, reduced antigenic load, nutritional effects, the provision of trophic amino acids, modification of gut flora, intestinal permeability, or fecal pH have been proposed. Equally, the fat profile of the feed may reduce pro-inflammatory ecosanoid synthesis and thus modify disease activity. Maintaining long-term remission remains a challenge in the management of this disease. Cyclic administration of enteral diets, maintenance drug therapy, fat manipulated formulas, or fish oil therapy may be strategies to prolong dietinduced remission. In the future, nutrient derivatives that play a role in the protective processes of the intestinal mucosa may have application in nutritional therapy in Crohn's disease.
Nutritional therapy in Crohn's disease
Inflammatory Bowel Diseases, 2007
The value of nutritional support in the prevention and treatment of malnutrition in Crohn's disease is undisputed but its role in primary therapy continues to be debated. Controlled trials have demonstrated that enteral nutrition induces remission rates comparable to that of corticosteroid therapy in Crohn's disease and remains the treatment of choice for specific subgroups such as children with signs of' growth impairment and patients with intolerable steroid-induced side effects. The mechanism by which an enteral diet induces remission in Crohn's disease is unclear. Bowel rest, reduced antigenic load, nutritional effects, the provision of trophic amino acids, modification of gut flora, intestinal permeability, or fecal pH have been proposed. Equally, the fat profile of the feed may reduce pro-inflammatory ecosanoid synthesis and thus modify disease activity. Maintaining long-term remission remains a challenge in the management of this disease. Cyclic administration of enteral diets, maintenance drug therapy, fat manipulated formulas, or fish oil therapy may be strategies to prolong dietinduced remission. In the future, nutrient derivatives that play a role in the protective processes of the intestinal mucosa may have application in nutritional therapy in Crohn's disease.
Nutritional Treatment in Crohn’s Disease
Nutrients, 2021
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) which can affect any part of the whole gastrointestinal tract (from mouth to anus). Malnutrition affects 65–75% of CD patients, and it is now well acknowledged that diet is of paramount importance in the management of the disease. In this review, we would like to highlight the most recent findings in the field of nutrition for the treatment of CD. Our analysis will cover a wide range of topics, from the well-established diets to the new nutritional theories, along with the recent progress in emerging research fields, such as nutrigenomics.
Bioactive Compounds in Health and Disease, 2018
Background:Ulcerative colitis, ileal, and colonic Crohn’s disease are the most common inflammatory bowel diseases (IBS). The etiology of this group of diseases is complex and is still not entirely elucidated. Nonetheless, IBS is at least partially attributed to microbiota imbalance, which leads to an abnormal immune response. Due to the gravity of this condition, its impact of quality of life, and its increasing incidence, many investigations have been conducted with respect to conventional and alternative treatments. While conventional medicine is partially beneficial, it is unable to completely control the disease. Frequent relapses, symptomatology often persists. Specific diets, functional foods, and herbal medicine may offer a solution to restore intestinal microbiota and gut health and ameliorate some symptomatology. This review will focus on the diagnosis and management of IBD with respect to functional foods, bioactive compounds, and the potential of conventional treatment. K...
Crohn’s disease - treatment with biological medication
Revista da Associação Médica Brasileira
1. Brazilian Study Group on Inflammatory Bowel Disease, Avenida Brigadeiro Faria Lima, 2391 CJ 102 -10 0 Andar -Jardim Paulistano, São Paulo -SP, Brasil 2. Brazilian Gastroenterology Federation, Avenida Brigadeiro Faria Lima, 2391 CJ 102 -10 0 Andar -Jardim Paulistano, São Paulo -SP, Brasil 3. Brazilian Coloproctology Society, Avenida Marechal Câmara, 160 sala 916 -Centro, Rio de Janeiro -RJ, Brasil http://dx.doi.org/10.1590/1806-9282.65.4.554